VCYT Stock: Price, Earnings History and SEC Filings
Veracyte, Inc. (VCYT) last traded at $50.01, down 4.14% on the latest session and up 8.6% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.37 against an analyst estimate of $0.29, a beat of 27.6%.
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
VCYT earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Jul 30, 2026 | $0.37 | $0.29 | +27.59% |
| Mar 2026 | May 5, 2026 | $0.37 | $0.23 | +60.87% |
| Dec 2025 | Feb 25, 2026 | $0.40 | $0.28 | +42.86% |
| Sep 2025 | Nov 4, 2025 | $0.38 | $0.19 | +100.00% |
VCYT beat the analyst EPS estimate in 4 of its last 4 reported quarters. Source: Nasdaq.
How VCYT reacts to earnings
Across its last 8 earnings releases, VCYT moved 14.8% on average the next session, in either direction. It rose after 6 of 8 reports.
| Report date | Released | Next-session move |
|---|---|---|
| 2026-07-30 | After close | -22.52% |
| 2026-05-05 | After close | +24.93% |
| 2026-02-25 | After close | +8.48% |
| 2026-01-12 | Before open | +3.35% |
| 2025-11-04 | After close | +27.46% |
| 2025-08-06 | After close | +15.48% |
| 2025-05-07 | After close | +1.20% |
| 2025-02-24 | After close | -14.99% |
Based on the dates of earnings-release 8-K filings (SEC EDGAR) and daily closing prices (Yahoo Finance). Past reactions do not predict future ones.
VCYT financial history
| Fiscal year | Revenue | Net income | Free cash flow | Net margin | Diluted EPS |
|---|---|---|---|---|---|
| 2025 | $517M | $66M | $127M | 12.8% | $0.82 |
| 2024 | $446M | $24M | $64M | 5.4% | $0.31 |
| 2023 | $361M | -$74M | $34M | -20.6% | $-1.02 |
| 2022 | $297M | -$37M | -$1M | -12.3% | $-0.51 |
| 2021 | $220M | -$76M | -$37M | -34.4% | $-1.11 |
| 2020 | $117M | -$35M | -$13M | -29.7% | $-0.66 |
| 2019 | $120M | -$13M | -$6M | -10.5% | $-0.27 |
| 2018 | $92M | -$23M | -$15M | -25.0% | – |
Source: annual figures from 10-K filings on SEC EDGAR. The year shown is the calendar year the fiscal year ended. Free cash flow is operating cash flow minus capital spending.
Latest SEC filings for VCYT
- 8-K · Sep 14, 2026Material agreement, Acquisition or disposal completed, Regulation FD disclosure
- 10-Q · Jul 31, 2026
- 8-K · Jul 30, 2026Results of operations, Financial statements and exhibits
- 8-K · Jun 11, 2026Officer or director change, Shareholder vote
- 10-Q · May 6, 2026
- 8-K · May 5, 2026Results of operations, Financial statements and exhibits
- DEF 14A · Apr 22, 2026
- 8-K · Mar 16, 2026Officer or director change
- 10-K · Feb 26, 2026
- 8-K · Feb 25, 2026Results of operations, Financial statements and exhibits
Insider filing activity
VCYT insiders filed 13 Form 4 reports in the last 90 days. A Form 4 is how directors and executives disclose purchases, sales and grants of company stock. See the individual filings on SEC EDGAR. Many Form 4 filings are routine, such as scheduled sales or option exercises, so check each filing before drawing a conclusion.
Source: SEC EDGAR.
VCYT news
- 4 Medical Stocks With a Healthy Shot at Q3 Earnings BeatsOct 30, 2026 · finance.yahoo.com
- Veracyte to Participate in Upcoming Investor ConferencesOct 29, 2026 · finance.yahoo.com
- Tandem Diabetes Care, Inc. (TNDM) May Report Negative Earnings: Know the Trend Ahead of Next Week's ReleaseOct 29, 2026 · finance.yahoo.com
- Veracyte (VCYT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Oct 28, 2026 · finance.yahoo.com
- Clinical Trial Data Might Change The Case For Investing In Veracyte Stock (VCYT)Oct 28, 2026 · finance.yahoo.com
- Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate CancerOct 23, 2026 · finance.yahoo.com
- Will Veracyte (VCYT) Beat Estimates Again in Its Next Earnings Report?Oct 21, 2026 · finance.yahoo.com
- Six Studies to Highlight Veracyte’s Genomic Tests Across Breast, Prostate and Bladder Cancer at ESMO 2026Oct 19, 2026 · finance.yahoo.com
About Veracyte, Inc.
Veracyte, Inc. (VCYT) is a US-listed public company on Nasdaq. The SEC classifies its business as Services-medical Laboratories. It is incorporated in DE. Its fiscal year ends in December.